• Iron Chelation In Myelodysplastic HSCT

    From ironjustice@cool.zzn.com@21:1/5 to All on Sat Apr 2 17:29:30 2016
    Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload.
    Zhonghua Xue Ye Xue Za Zhi. 2016 Mar 14;37(3):189-193. doi: 10.3760/cma.j.issn.0253-2727.2016.03.003.
    Gu CH1, Li CX, Ye L, Liu H, Ma JF, Wang T, Zou Q, Chen J, Chen XC, Wu DP.

    Abstract
    Objective: To investigate the effects of iron chelation therapy on hematopoietic reconstitution and related complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic syndrome (MDS).
    Methods: Various clinical parameters were analyzed retrospectively in 57 MDS patients with iron overload who received allo-HSCT. According to the level of serum ferritin (SF) before transplantation divided patients into two groups: the effective
    treatment group (SF<1 000 μg/L) and iron overload group (SF≥1 000 μg/L). Results: ①30/57 cases were received iron chelation treatment, 27/57 patients didn' t received iron chelating therapy before transplantation. 19/30 cases were in the effective treatment group, and the median SF level before transplantation was 561 (223-
    846) μg/L. 11/30 cases were in the iron overload group, and the median SF level before transplantation was 1 262 (1 100-2 352) μg/L. The median SF level was 1 540 (1 320-3 112) μg/L of 27 patients didn't received iron chelating therapy before
    transplantation. ② The rate of fully-engraftment in the effective treatment group and iron overload group was 19 cases (100.0% ) and 34 cases (89.5% ), myeloid reconstitution of 12(10-18) and 12(11-30) days respectively (P=0.441), and platelet
    reconstitution of 13(12-30) and 15 (10-32) days respectively (P=0.579). ③The infection risk rate of the effective treatment group was less than iron overload group [36.8% (7/19) vs 82.4% (28/34), P=0.002]. ④The incidence of aGVHD in effective
    treatment group was less than iron overload group [26.3%(5/19) vs 64.7%(22/34), P= 0.010]. All patients of the effective treatment group were Ⅰ/Ⅱ degree. 16 cases were Ⅰ/Ⅱ degree and 6 cases were Ⅲ/Ⅳ degree in the iron overload group. ⑤ 6
    cases of iron overload group accepted iron chelation treatment early post-transplantation, and SF level decreased from 2 870 (2 205-3 580) μg/L to 1 270 (1 020-1 650) μg/L. ⑥The difference of median disease-free survival time between the effective
    treatment group and iron overload group was not statistically significant [28.9 (0.3-89.5) months vs 21.2(0.1-81.0) months, χ2=3.751, P=0.053].
    Conclusions: Iron overload obviously increased transplant-related complications, and effective iron chelation therapy before transplantation significantly decreased the incidence of infection and degree of aGVHD, thereby reduced the non-relapse mortality
    in patients with MDS.

    PMID: 27033754

    Who loves ya.
    Tom

    Jesus Was A Vegetarian!
    http://tinyurl.com/634q5a

    Man Is A Herbivore!
    http://tinyurl.com/4rq595

    DEAD PEOPLE WALKING
    http://tinyurl.com/zk9fk

    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)